TScan Therapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing; the filing separately reports a fourth-quarter net loss of $18.7 million.
Business context
TScan is a clinical-stage biotechnology company developing engineered T-cell receptor (TCR-T) therapies for cancer. It has no approved products and has not generated product-sales revenue. Its lead candidates, TSC-100 and TSC-101, target hematologic malignancies after stem-cell transplantation; its solid-tumor program is intended to enable customized combinations of TCRs.
Financial results and liquidity
| Metric (USD millions, except per-share data) | FY2022 | FY2021 |
|---|---|---|
| Collaboration and license revenue | 13.5 | 10.1 |
| Research and development expense | 59.8 | 45.0 |
| General and administrative expense | 20.4 | 13.8 |
| Total operating expenses | 80.2 | 58.8 |
| Operating loss | (66.6) | (48.6) |
| Net loss | (66.2) | (48.6) |
| Basic and diluted net loss per share | (2.75) | (4.17) |
| Cash used in operating activities | (66.5) | (48.7) |
| Cash used in investing activities | (4.2) | (9.9) |
| Cash provided by financing activities | 29.4 | 189.7 |
Revenue came from collaboration and licensing arrangements, principally Novartis; there were no product sales. The filing does not report a meaningful product gross margin.
At year-end, cash and cash equivalents were $120.0 million, restricted cash was $5.0 million, and current assets and current liabilities were $124.1 million and $17.3 million, respectively. Accumulated deficit was $158.4 million. Management estimated existing cash would fund operating expenses and capital requirements into the second quarter of 2024, based on its then-current plan; the filing cautions that assumptions could change.
Long-term debt and accrued interest totaled $29.3 million. The September 2022 K2 HealthVentures agreement provides up to $60 million in tranches: $30 million was drawn, a further $10 million is milestone-dependent, and a $20 million tranche is uncommitted. The loans bear interest at a rate capped at 9.90% under the stated formula, have a September 2026 maturity, and include a 6% final fee. The agreement is secured by substantially all assets other than intellectual property and includes operating restrictions and a minimum-liquidity covenant. Operating lease liabilities were $56.7 million, with undiscounted future payments of $89.7 million.
Changes versus FY2021
- Revenue increased by $3.4 million, or about 33%, reflecting the timing of Novartis research activities.
- Operating expenses rose by $21.4 million, or about 36%; R&D growth reflected staffing, facilities and equipment expansion, and Phase 1 start-up costs.
- Net loss widened by $17.6 million, or about 36%. R&D expense increased $14.9 million and G&A increased $6.5 million.
- Operating cash use increased by $17.8 million. Financing cash inflow fell sharply from 2021, which included the IPO and preferred-stock proceeds; 2022 financing was primarily the K2HV loan.
Outlook, commentary and material risks
- Hematologic program: The company had initiated a multi-arm Phase 1 study of TSC-100 and TSC-101, with sites activated; it had not yet dosed patients in this program as of February 28, 2023. Management expected safety and biomarker updates in 2023, further data and recommended Phase 2 doses by year-end 2023, and relapse-prevention data in 2024.
- Solid-tumor program: FDA-cleared INDs for T-Plex and two TSC-204 candidates enabled study start-up. Management expected screening to begin by mid-2023, dosing in the third quarter, initial safety and biomarker data by year-end 2023, and initial multiplexed-therapy data in the first half of 2024. These are forward-looking plans, not reported outcomes.
- The company expects continued operating losses and says substantial additional funding will be required to complete development and commercialization. The Novartis research term was expected to conclude in March 2023; $3.9 million of deferred revenue was current at year-end. Potential option fees, milestones and royalties are contingent and are not assured revenue.
- Key risks include clinical safety or efficacy failure, delays or enrollment challenges, manufacturing quality and scale-up, reliance on limited suppliers and third parties, financing availability and loan covenants, competition, and early-stage intellectual-property protection. Cell therapy risks include off-target effects, graft-versus-host disease, autoimmune reactions and gene-integration risks. Solid-tumor activity remains unproven.
- The company reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective at the reasonable-assurance level; the auditor did not provide an internal-control attestation.
Investor verification priorities
- Check subsequent clinical disclosures against the stated 2023–2024 timelines, including patient dosing, safety, biomarkers, dose selection and relapse outcomes.
- Assess cash burn, financing needs and actual runway against management’s estimate, and review compliance with K2HV’s liquidity covenant, repayment terms and potential dilution from conversion.
- Confirm the Novartis collaboration’s status, remaining option rights and any resulting payments; distinguish contingent milestones and royalties from recognized revenue.
- Review lease commitments and restricted cash, and monitor whether facility and manufacturing capacity support planned clinical programs.
- Evaluate whether TCR-T safety, efficacy, manufacturability and patent protection are substantiated by clinical and regulatory evidence rather than company expectations.